Protocol Overview
Dosing Protocol
Conservative Start
100 mcg
1x daily (before bed)
Subcutaneous
Weeks 1–2 only
Standard Protocol
100–200 mcg
2x daily (pre-workout + before bed)
8–12 weeks
Optimized Protocol
100–300 mcg
3x daily (pre-workout, post-workout, before bed)
Key principle: CJC-1295 No DAC works best when combined with a GHRP (Ipamorelin, GHRP-2, or Hexarelin) administered at the same time. The GHRH + GHRP combination produces synergistic GH release far exceeding either compound alone. Administer on an empty stomach, as elevated blood sugar and insulin blunt GH release.
Reconstitution Instructions
Materials Needed
CJC-1295 No DAC 2mg lyophilized vial
Bacteriostatic water (2mL)
3mL mixing syringe (18-20ga)
Insulin syringes (29-31ga) for dosing
Alcohol swabs
Reconstitution Steps
Clean vial stopper with alcohol
Draw 2mL bacteriostatic water
Inject slowly down the vial wall
Gently swirl (never shake)
Wait 5 minutes for full dissolution
Concentration: 1,000 mcg/mL
50 mcg
0.05 mL
5 units
0.10 mL
10 units
200 mcg
0.20 mL
20 units
500 mcg
0.50 mL
50 units
Administration Guide
Injection Sites
Abdomen: Primary site, subcutaneous
Thigh: Outer thigh, alternate sides
Upper arm: Back of arm, alternate
Timing & Storage
Timing: Fasted state only — 2+ hrs after eating. Best windows: pre-workout, post-workout, and/or before bed
Half-life: Only ~30 min — 2–3x daily dosing maximizes GH pulse amplitude vs. once daily
Fasted state: Critical — elevated insulin blunts GH release entirely
Vial duration: ~6–7 days at 300mcg/day (3x daily); ~10 days at 200mcg/day
Storage (reconstituted): Refrigerate 2-8°C, use within 20 days
Do not freeze reconstituted solution
Expected Timeline
Side Effects & Monitoring
Common Side Effects
Injection site redness (mild, transient)
Flushing or warmth after injection
Mild headache (uncommon)
Water retention at higher doses
CJC-1295 No DAC is generally well-tolerated with a favorable side effect profile. Unlike GHRPs, it does not significantly raise cortisol or prolactin.
Precautions
Does not cause receptor desensitization (unlike some GHRPs)
May elevate IGF-1 - monitor in subjects with cancer history
Not recommended during pregnancy or breastfeeding
Use caution with diabetes - GH affects insulin sensitivity
Avoid high-carb meals near injection time
Stacking Recommendations
Compatible Compounds
Ipamorelin: Gold standard GHRH + GHRP pairing for synergistic GH
GHRP-2: Stronger GH release with moderate appetite increase
Hexarelin: Maximum GH pulse (cycle to avoid desensitization)
BPC-157: Tissue repair during recovery protocols
AOD-9604: Fat loss synergy without IGF-1 elevation
Popular Stacks
Classic GH: CJC-1295 No DAC 100mcg + Ipamorelin 100mcg before bed
Recovery: CJC/Ipa stack + BPC-157 250mcg + TB-500
Anti-Aging: CJC/Ipa + Epithalon for telomere + GH support
Blood Work Recommendations
GH Axis
IGF-1, GH (fasting)
Baseline, Week 6, Week 12
Metabolic
Fasting glucose, insulin, HbA1c
Baseline, Week 6
Basic Panel
CBC, CMP
Baseline, Week 8
Thyroid
TSH, Free T3, Free T4
IGF-1 is the primary marker for sustained GH output and confirms protocol effectiveness. Metabolic markers help track insulin sensitivity changes from elevated GH.
Related Tools & Resources
Related Resources